Intoxication with three different superwarfarin compounds in an adult woman

• References

• 1 Caravati EM. et al. Long-acting anticoagulant rodenticide poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2007; 45: 1-22.
• 2 Sharma P, Bentley P. Of rats and men: superwarfarin toxicity. Lancet 2005; 365: 552-553.
• 3 Chua JD, Friedenberg WR. Superwarfarin poisoning. Arch Intern Med 1998; 158: 1929-1932.
• 4 International Programme on Chemical Safety. Brodifacoum. http://www.inchem.org/documents/pds/pds/pest57_e.htm Accessed on February 18, 2008
• 5 Watson WA. et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005; 23: 589-666.
• 6 Weitzel JN. et al. Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases. Blood 1990; 76: 2555-2559.
• 7 Park BK. et al. Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins. Br J Clin Pharmacol 1986; 21: 289-293.
• 8 Spiller HA. et al. Dermal absorption of a liquid diphacinone rodenticide causing coagulaopathy. Vet Hum Toxicol 2003; 45: 313-314.
• 9 Waien SA. et al. Severe coagulopathy as a consequence of smoking crack cocaine laced with rodenticide. N Engl J Med 2001; 345: 700-701.
• 10 Laposata M. et al. Case 1–2007. A 40-year-old woman with epistaxis, hematemesis, and altered mental status. N Engl J Med 2007; 356: 174-182.
• 11 Pavlu J. et al. Superwarfarin poisoning. Lancet 2005; 365: 628.
• 12 Kotsaftis P. et al. Haemarthrosis after superwarfarin poisoning. Eur J Haematol 2007; 79: 255-257.
• 13 Hoffman RS. et al. Evaluation of coagulation factor abnormalities in long-acting anticoagulant overdose. J Toxicol Clin Toxicol 1988; 26: 233-248.
• 14 Tsutaoka BT. et al. Superwarfarin and glass ingestion with prolonged coagulopathy requiring high-dose vitamin K1 therapy. Pharmacotherapy 2003; 23: 1186-1189.
• 15 Geisen C. et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005; 94: 773-779.
• 16 Oldenburg J. et al. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98: 570-578.
• 17 Vecsler M. et al. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 2006; 95: 205-211.